Jun 15, 2020
Emmes Announces Its Work on a Phase 3 Clinical Trial for Breakthrough Therapy Designation Product
Jun 12, 2020
EHA25Virtual: Promising Treatment Results with Imetelstat, a Novel Telomerase Inhibitor, in Patients with Lower Risk Myelodysplastic Syndromes
Jun 10, 2020
Ryvu Therapeutics Reports First Quarter 2020 Financial Results
May 14, 2020
Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress
May 14, 2020
Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS)
Mar 28, 2020
Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia
Feb 21, 2020
Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)
Feb 03, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
Dec 18, 2019
Specialised Therapeutics Signs Exclusive Deal for New Haematology Drug
Nov 19, 2019
Biosight Announces Data to be Presented at ASH 2019 Annual Meeting
Nov 06, 2019
Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019
Sep 06, 2019
Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Jul 31, 2019
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
Jul 25, 2019
Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Jun 17, 2019
Data Presented At 24 Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients
Jun 12, 2019
Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS
Jun 04, 2019
Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting
May 16, 2019
Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress
May 16, 2019
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
Apr 25, 2019
Health Union Survey Reveals Half of Blood Cancer Cases Detected from Symptoms, Other Half Incidental